|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Areas covered</b>: Several studies demonstrated the ability of 5-ASA to induce endoscopic remission to a similar extent as anti-TNF therapy on the moderate segment of UC.
|
31498003 |
2020 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
5-ASA to sulfasalazine drug switch program in patients with ulcerative colitis.
|
30020742 |
2018 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
5-ASA may have beneficial effects on the mucosal microbiome, and high concentrations possibly amend dysbiosis in UC.
|
30895635 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A dose reduction of 5-ASA might be cautiously selected in UC patients with a history of steroid use and a shorter duration of disease remission.
|
29108025 |
2017 |
|
Ulcerative Colitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Abbreviations: ADA: Adalimumab; CD: Crohn disease; ECCO: European Crohn's and Colitis Organisation; EEN: exclusive enteral nutrition; ESPGHAN: European Society for Paediatric Gastroenterology Hepatology and Nutrition; FMT: faecal microbiota transplantation; GDP: gross domestic product; HIC: high-income countries; IBD: inflammatory bowel disease; IBDU: inflammatory bowel disease unclassified; IC: ileocolonoscopy; IFX: infliximab; IPAA: ileal pouch anal anastomosis; LMIC: low- and middle-income countries; MH: mucosal healing; OGD: oesophago-gastroduodenoscopy; PCDAI: Paediatric Crohn's Disease Activity Index; PIBD: paediatric inflammatory bowel disease; PUCAI: Paediatric Ulcerative Colitis Activity Index; UC: ulcerative colitis; UGIT: upper gastrointestinal tract; VEO-IBD: very early-onset IBD; WLE: white light endoscopy; 5-ASA: 5 aminosalicylic acid; 6-MP: 6-mercaptopurine.
|
30900526 |
2019 |
|
Ulcerative Colitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Adult UC outpatients treated with oral 5-ASA products were enrolled from 379 sites in Japan between July 2012 and July 2013, and followed for 52 weeks.
|
28390410 |
2017 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
All patients had mild-to-moderate UC and were undergoing long-term 5-ASA maintenance.
|
30478770 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
An increase in the use of topical 5-ASA therapy in UC patients was noted over time from 5% to 38%.
|
28644308 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Can we move directly from 5-ASA to a biologic agent in ulcerative colitis?
|
30060944 |
2018 |
|
Ulcerative Colitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Concentrations of thioguanine nucleotides (TGN) and methymercaptopurine nucleotides (MMPN), metabolites of thiopurines, were measured by high performance liquid chromatography in 12 young patients (3 females and 9 males, median age 16 years) with inflammatory bowel disease (6 Crohn's disease and 6 ulcerative colitis) treated with thiopurines (7 mercaptopurine and 5 azathioprine) and 5-ASA.
|
25834322 |
2015 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Costs for CD patients were significantly higher than those for UC regarding all direct expenditures (except for 5-ASA and diagnostic expenses).
|
31076743 |
2020 |
|
Ulcerative Colitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Discrepancies between guidelines and management were found in: 25/80 (31%) of patients with UC in remission receiving oral 5-aminosalicyclates (5-ASAs) as maintenance therapy, and; 46/110 (42%) of patients with small bowel and/or ileo-cecal CD receiving 5-ASA.
|
28128675 |
2017 |
|
Ulcerative Colitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Drug regimens applied in the year before index hospitalization were as follows: no IBD drugs (43.6% ulcerative colitis, 43.1% Crohn's disease); 5-ASA (45.7% ulcerative colitis, 19.1% Crohn's disease); local steroids (17.9% ulcerative colitis, 17.6% Crohn's disease); systemic steroids (38.6% ulcerative colitis, 29.4% Crohn's disease); immunomodulators (10.7% ulcerative colitis, 18.1% Crohn's disease); biologics (10% ulcerative colitis, 24% Crohn's disease); and calcineurin inhibitors (2.1% ulcerative colitis, 1.5% Crohn's disease).
|
31834046 |
2020 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Focused questions included the following: (1) comparative effectiveness and tolerability of different oral 5-ASA therapies (sulfalsalazine vs diazo-bonded 5-ASAs vs mesalamine; low- (<2 g) vs standard (2-3 g/d) vs high-dose (>3 g/d) mesalamine); (2) comparison of different dosing regimens (once-daily vs multiple times per day dosing) and routes (oral vs rectal vs both oral and rectal); (3) role of oral budesonide in patients mild-moderate UC; (4) comparative effectiveness and tolerability of rectal 5-ASA and corticosteroid formulations in patients with distal colitis; and (5) role of alternative therapies like probiotics, curcumin, and fecal microbiota transplantation in the management of mild-moderate UC.
|
30576642 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, the 5-ASA-HSA NPs group containing one thousandth of the dose of the 5-ASA (75 μg/kg) showed significantly lower disease activity index values and colon weight/length ratios in UC model mice as similar to large amount of neat 5-ASA group (75 mg/kg), indicating that the therapeutic effect of the 5-ASA-HSA NP formulation was confirmed in vivo.
|
29407223 |
2018 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the combined use of topical 5-ASA and BDP proved to be the best choice for active distal UC and further well-designed researches are warranted to assess its efficacy and safety.
|
28440311 |
2017 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, 5-ASA was more effective than placebo in both induction and maintenance treatment of UC, but there were conflicting results on the effect of 5-ASA on the induction treatment or relapse of CD.
|
30844556 |
2019 |
|
Ulcerative Colitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Kaplan-Meier analysis showed that the event-free survival (exacerbation of disease activity) of UC patients treated with biologics and 5-ASA (n = 42) was not significantly lower than that of those taking biologics alone (n = 21) (log rank test, P = 0.68).
|
31471699 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mesalamine (5-ASA) is widely used for the treatment of ulcerative colitis, a remitting condition characterized by chronic inflammation of the colon.
|
23146664 |
2013 |
|
Ulcerative Colitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mesalamine (5-ASA) consists of the first-line therapy for the treatment of ulcerative colitis; however, it has low bioavailability, can cause several systemic adverse events, and has low treatment adherence due to the inconvenient dosing scheme.
|
28958891 |
2018 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mesalamine (5-aminosalicylic acid, 5-ASA) is known to be the first-line medication for treatment of patients with ulcerative colitis.
|
23529546 |
2013 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
NAE-PPARα signaling system is impaired during active UC and 5-ASA/glucocorticoids treatment restored its normal expression.
|
22662201 |
2012 |
|
Ulcerative Colitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Observational, cohort study of ulcerative colitis (UC) patients in clinical remission at least 6 months on 5-ASA monotherapy maintenance prescribed by an electronic management program.
|
30963247 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Only one meta-analysis evaluated clinical remission maintenance, showing no statistically significant difference between MTX and placebo, 5-ASA, or 6-MP in UC.
|
30863001 |
2019 |
|
Ulcerative Colitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with UC who started anti-TNF after having been on oral 5-ASA for at least 90 days were included.
|
30420398 |
2019 |